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a b s t r a c t
Evaluation of antigen-specific T-cell responses to viral antigens is frequently performed on IFN-c secret-
ing cells. However, T-cells are capable of producing many more functions than just IFN-c, some of which,
like Perforin, are associated with immune protection in HIV-1 disease elite controllers. We evaluated the
extent of missed T-cell functions when IFN-c secretion is used as a surrogate marker for further evalua-
tion of T-cell functions. Intracellular cytokine staining assay and flow cytometry were used to assess
peripheral blood mononuclear cells (PBMCs) from 31 HIV-infected ART-naive individuals for the extent
to which gated CD4+ and CD8+ IFN-c producing and non-producing T-cells also secreted IL-2, Perforin,
and TNF-a functions. Similarly, the extent of missed virus-specific responses in IFN-c ELISpot assay neg-
ative T-cells from 5 HIV-1 uninfected individuals was evaluated. Cells from HIV-infected individuals were
stimulated with pooled consensus group M (Con M) peptides; and those from healthy individuals were
stimulated with pooled adenovirus (Ad) peptides. Overall, frequencies of virus-specific IFN-c secreting
CD4+ and CD8+ cells were low. Proportions of IFN-c negative CD4+ expressing IL-2, Perforin, or TNF-a
to Con M were significantly higher (5 of 7 functional profiles) than the corresponding IFN-c positive
CD4+ (0 of 7) T-cell phenotype, p = 0.02; Fisher’s Exact test. Likewise, proportions of CD8+ T-cells express-
ing other functions were significantly higher in 4 of the 7 IFN-c negative CD8+ T-cells. Notably, newly
stimulated Perforin, identified as Perforin co-expression with IL-2 or TNF-a, was significantly higher in
IFN-c negative CD8+ T-cell than in the positive CD8+ T-cells. Using SEB, lower responses in IFN-c positive
cells were most associated with CD4+ than CD8+ T-cells. These findings suggest that studies evaluating
immunogenicity in response to HIV and Adenovirus viral antigens should not only evaluate T-cell respon-
siveness among IFN-c producing cells but also among those T-cells that do not express IFN-c.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
T-cells exert strong selective pressure on HIV replication [1]. In
HIV-1 infected persons, their emergence coincides with reduced
acute-phase plasma viremia, and their depletion is linked to loss
of control of viral replication [1,2]. Designing an effective T-cell
based vaccine to prevent HIV acquisition requires understanding
and detecting those T-cell functions that contribute to protection.
The IFN-c ELISpot assay is a cost-effective method for detecting
HIV-specific T-cell responses [3,4]. However, this assay was opti-
mized to detect only IFN-c production. Attempts to use ELISpot
to distinguish dual cytokines detected significantly lower IFN-c
than when this function was evaluated alone [5]. While identifying
T-cell responses by initially screening with the IFN-c ELISpot assay
is a robust and cost effective approach; it assumes that other virus-
specific T-cell functions predominantly simultaneously express
with IFN-c. There are several limitations to using IFN-c expression
as a surrogate marker for further assessment of other T-cell
responses to viral challenge. First, the detected IFN-c responses
are usually narrowly directed [6,7]; in some cases, IFN-c produc-
tion positively correlates with enhanced viral replication [8], and
its secretion does not always correlate with CD8+ T-cell cytolytic
activity [9,10]. Besides, most virus-specific IFN-c producing cells
are mono-functional, terminally differentiated T-cells that may
be linked to poor clinical prognosis in HIV-infected patients
[11–14]. Finally, virus-specific IFN-c expression failed to predict
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vaccine protection in a Phase III Step Study trial that evaluated effi-
cacy of the MRKAd5 HIV-1 gag/pol/nef vaccine [4]. In that vaccine
trial, T-cells isolated from 75% of the vaccinated individuals
expressed IFN-c [4], but the vaccine failed to protect them from
acquiring HIV-infection. It remains unclear what the extent of
missed detection is when you rely on IFN-c expression as a repre-
sentative surrogate for evaluating other co-expressed functional
correlates of protection from HIV-1 disease.
On the other hand, expression of other T-cell functions, such as
Perforin and MIP-1b, has been correlated with reduced viral load
and slower disease progression in HIV-1 elite-controllers [15,16].
Likewise, Interleukin 2 (IL-2) expression has been shown to acti-
vate natural killer (NK) cells leading to apoptosis of HIV-1 infected
T-cells; and to enhance proliferation of HIV-1 specific CD8+ T-cells
[17,18]. Additionally, tumor necrosis factor-a (TNF-a) has been
linked to protection by inducing apoptosis of virally infected target
cells [19]. Therefore, many other cytokines are necessary for an
effective host response to virus infection.
Evaluation of other cellular immune functions is commonly
performed only among those T-cells initially identified to be IFN-
c secreting using the ‘back-gating’ procedure of flow cytometry
analysis [20], or using ELISpot assay screening for individuals with
positive IFN-c secretion [21–25]. Proportions of CD4+ and CD8+ T-
cells that lack expression of IFN-c (IFN-c negative) but secrete
other T-cell functions in response to viral antigens have not been
well studied. Thus, we have evaluated the potential extent of miss-
ing detection of virus-specific expression of IL-2, Perforin, and TNF-
a by IFN-c non-secreting T-cells, when IFN-c is used as a surrogate
for further T-cell functional evaluation. We evaluated the contribu-
tion of IFN-c negative T-cells using a diseased state model repre-
sented by HIV-1 infected populations, and the extent of missed
detection in a healthy immune system model represented by indi-
viduals that would ideally qualify for participation in vaccine clin-
ical trials.
2. Materials and methods
2.1. Study participants
This study obtained residual PBMC specimens from two earlier
MRC/UVRI cross-sectional cohorts, whose participants had previ-
ously consented to donate blood for use in future HIV-1 vaccine
discovery research studies. One cohort comprised subjects who
were chronically infected with HIV-1; these were used to model
assessment of immune responses to disease. The second cohort
comprised healthy HIV-uninfected volunteers selected according
to the standard inclusion criteria for selecting healthy HIV-1 vac-
cine trials volunteers, to model assessment immune responses in
healthy participants of clinical trials [26].
The HIV-1 infected cohort was recruited as part of a multi-
center study to evaluate whether consensus group M peptides
could be used to detect HIV-1 specific responses at similar frequen-
cies across geographical regions of Uganda, South Africa, Camer-
oon, and Ethiopia diverse infecting HIV strains [27]. This was
done because the different locations possessed completely differ-
ent clades of circulating HIV-1 strains making it even more compli-
cated to globally assess HIV-specific immune responses across sites
with differing strains. This parent cohort enrolled 50 HIV-1 chron-
ically infected, antiretroviral drug (ART) naïve adult men and
women that were seeking voluntary HIV counseling and testing
services at the Uganda Virus Research Institute (UVRI), and The
AIDS Support Organization (TASO) clinics in Entebbe, Uganda,
between August and September 2007.
The parent healthy cohort comprised 59 healthy HIV-
uninfected adult men and women that were recruited from the
UVRI clinic. The healthy volunteers were selected using similar cri-
teria to that used for selecting HIV vaccine trial participants, as part
of a multicenter trial (3 sites in Africa and one USA site) to evaluate
extents of preexisting immune responses to chimpanzee Aden-
oviruses. They were previously shown to exhibit pre-existing anti-
bodies to Adenoviruses, with median antibody titres of 190, IQR
20-330 [26], as evidence for prior exposure.
After obtaining signed informed consent, venous blood was
obtained from each participant from both the cohorts. These study
objectives were reviewed and approved by the institutional UVRI
Science and Ethics Committee and the Uganda National Council
of Science and Technology.
2.2. Study samples
We used peripheral blood mononuclear cells (PBMCs) that were
previously isolated from whole blood using Ficoll density gradient
centrifugation, and cryopreserved as described before [27]. Here,
cryopreserved PBMCs were thawed, rested overnight, and stimu-
lated with either pooled Con M peptides (HIV-1 infected cohort),
or Adenovirus 5, 6 or 7 peptides (healthy cohort) to quantify secre-
tion of virus-specific IFN-c using the IFN-c ELISpot assay. PBMC
specimens that secreted IFN-c (IFN-c positive) in response to
Con M (n = 31), and those that lacked IFN-c responses (IFN-c neg-
ative) to Ad peptides (n = 5) were selected for further evaluation of
other functions using flow cytometry, as summarized in Fig. 1.
One of the inclusion criteria for HIV-infected volunteers at that
time was having CD4 cell counts of 350 cell/ll. The 31 HIV-
infected persons included in this analysis had median CD4 cell
counts of 538 cell/ll (IQR 484–647), and median plasma viral loads
of 15,550 RNA copies/ml (IQR 3450–52,400).
2.3. Use of IFN-c ELISpot assay to screen for virus-specific IFN-c
responses to synthetic peptides
To quantify secretion of virus-specific IFN-c response to Con M,
we used 129 HIV-1 group M consensus peptides that were 14–16
amino acids long, overlapping by 11 amino acids, and spanning
the entire length of the HIV Gag protein. These peptides were
obtained from the USA NIH AIDS Reference Reagent Repository
(Cat No. 11057; https://www.aidsreagentorg/Index.cfm). Con M
peptides were selected because they were previously shown to
detect comparable frequencies of HIV-specific CD4+ and CD8+ T-
cell responses as consensus clade A and D peptides, in this popula-
tion with mixed HIV clade A and D infection [27], supplementary
figure 1A and 1B. Synthetic peptides were pooled and used in
duplicate wells containing 100,000 PBMCs/well, with each individ-
ual peptide occurring at a final concentration of 2 lg/ml. A pool
and matrix layout was used to ensure that each peptide occurred
in two different wells, as previously described [27]. ELISpot plates
were developed using Nova-Red substrate (Vector, Burlingame, CA)
according to the manufacturer’s protocol. IFN-c responses to pep-
tide pools were quantified as spot-forming units per million PBMCs
(SFU/106 PBMCs). The test acceptance criteria were 300 SFU/106
PBMCs in each phyto-hemagglutinin (PHA) positive control well;
100 SFU/106 PBMCs in all six-background wells; and 5 cumula-
tive SFU/106 PBMCs in the two wells containing media only. Test
wells with net responses 100 SFU/106 PBMC after subtracting
three times the background SFU values were considered positive
for IFN-c production. Net responses below 100 SFU/106 PBMCs
were considered negative for IFN-c secretion, and were set to zero
SFU/106 PBMC for purposes of easing data analysis.
To quantify Adenovirus-specific IFN-c responses; synthetic ade-
novirus peptides that were 14–15 amino acids long overlapping by
10 amino acids were used. These peptides were obtained from Pro-
fessor Ertl Hildegund C. J, Wistar Institute, Philadelphia, Pennsylva-
nia, United States. Adenovirus (Ad) peptides traversed the
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conserved and variable hexon regions of Ad-serotype 5 (Ad5), Ad-
serotype 6 (Ad6) and Ad-serotype 7 (Ad7). Up to 49 peptides were
grouped by serotype, to generate four pools traversing the con-
served hexon region, and one pool traversing the variable hexon
region. A positive IFN-c T-cell response was determined as
described for HIV above.
2.4. PBMC stimulation and intracellular cytokine staining for flow
cytometry
Cryopreserved PBMCs from previously defined IFN-c ELISpot
positive specimens to Con M (n = 31) and previously determined
IFN-c ELISpot negative specimens to Adenovirus (n = 5) were
thawed, rested overnight and stimulated with Con M and Ad pep-
tides, respectively, before they were further evaluated for other
functions using flow cytometry. All PBMCs were stimulated with
their respective antigens for 6 h at 37 C in a 5% CO2 incubator;
and stained with specified fluorochrome antibodies, as previously
described [25]. Briefly, trypan blue exclusion counting was used
to select groups of 500,000 live PBMCs. These were then incubated
with: (1) media only as negative controls; (2) media containing
pools of 2 lg/ml per peptide as test wells; or (3) media containing
2 lg/ml Staphylococcal enterotoxin B (SEB) (Sigma-Aldrich Logistic
GmbH, Germany) as positive controls, in the presence of 10 lg/ml
Golgi PlugTM and 1 lg/ml co-stimulatory antibodies CD28 and CD49
(BD Biosciences). After stimulation, the PBMCs were washed and
stained with Aqua (L34957, Invitrogen), CD19 APC Alexafluor 750
(1072337A, Invitrogen), and CD14 APC Alexafluor750 antibodies
(773927B, Invitrogen) to eliminate dead cells, B cells, and mono-
cytes, respectively. The T-cells were defined using surface markers
for CD3 (brilliant violet 570, B152103, Biolegend), CD8 (pacific
blue, 22416, BD Bioscience) and CD4 (PE-Cy5.5, 1049514A, eBio-
sciences). Intracellular secretion of T-cells functions was quantified
using Alexafluor 700, 21128, BD Bio- sciences (IFN-c), APC,
341116BD Biosciences (IL-2), FITC B-D48 clone, F111124, Diaclone
(Perforin) and PE-Cy7 antibodies, E07677-1632, ebiosciences (TNF-
a). Up to 500,000 events were acquired on a custom-built, 18-color
LSR II flow cytometer (BD Biosciences) using a threshold of 5000 on
Forward Scatter Area (FSC-A).
2.5. Flow cytometry data analysis
Flow cytometry datasets were analyzed with FlowJo software
(FlowJo Treestar, version 9.7.4), using the gating strategy illus-
trated in Fig. 2. At least 300,000 lymphocytes (median 510,000;
interquartile range [IQR] 430,000–520,000) were hierarchically
gated to delineate CD4+ (CD3+CD8CD4+) and CD8+ (CD3
+CD4CD8+) T-cells. Briefly, we first gated the lymphocytes,
removed duplexes to select only single cells, and finally eliminated
dead cells, B cells, and monocytes, Fig. 2A. IFN-c secretions from
non-CD3+ T-cells were eliminated, while all IFN-c positive and
negative CD3+ T-cells were selected for further stratifications.
We then eliminated double positive (CD4+CD8+) T-cells to select
pure singly stained CD4+ (CD3+CD8CD4+) and CD8+ (CD3
+CD4CD8+) T-cells, Fig. 2B. CD4+ and CD8+ cells were then delin-
eated with FlowJo Software to quantify proportions of functional
Fig. 1. Model for selection and evaluation of specimens for antigen-specific T-cell immune responses. This figure illustrates the screening for T-cell responses using the
Interferon gamma (IFN-c) ELISpot assay, and subsequent use of flow cytometry to evaluate co-expressing responses. Arm A denotes stimulation of PBMCs from HIV-1 infected
individuals with consensus group M peptides. After flow cytometry, T-cells in Arm A were stratified into IFN-c secreting (IFN-c positive) and non-secreting (IFN-c negative)
populations. Secretion of other T-cell functions (Perforin, TNF-a and IL-2) was then compared across the two groups. Arm B comprised healthy HIV-1 uninfected individuals,
serologically reactive to Adenovirus by antibody testing, but IFN-c ELISpot negative to Adenovirus peptide stimulation. The IFN-c negative T-cells were assessed for
expression of Adenovirus-specific Perforin, TNF-a,and IL-2 using flow cytometry.
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cells. T-cell functions were defined using SEB stimulation guided
gates (representing maximum activation), and unstimulated
specimen-guided gates (representing background activation). Per-
forin lacked well-defined separation; therefore, we also used
Flouresence minus One (FMO) controls and titration data to guide
the gates for Perforin, supplementary Fig. 2. In a more stringent
analysis, we perceived singly expressed Perforin responses as pre-
formed and considered only Perforin co-expressed with another
function as newly secreted. Boolean gating was used to distinguish
the responding T-cells into 16 subsets of functions comprising
polyfunctional, singly expressing, and non-functional subsets.
Boolean gating delineated eight distinct subsets of IFN-c positive
co-expressing functions: IFNc+IL2+Perf+TNFa+, IFNc+IL2+Perf+TN
Fa, IFNc+IL2+Perf-TNFa+, IFNc+IL2+PerfTNFa, IFNc+IL2Perf
+TNFa+, IFNc+IL2Perf+TNFa, IFNc+IL2PerfTNFa+, IFNc+IL2
PerfTNFa. Similarly, eight functional subsets of IFN-c negative
cells were delineated as follows: IFNcIL2+Perf+TNFa+, IFNcIL2+
Perf+TNFa, IFNcIL2+PerfTNFa+, IFNcIL2+PerfTNFa,
IFNcIL2Perf+TNFa+, IFNcIL2Perf+TNFa, IFNcIL2Perf
TNFa+, and IFNcIL2PerfTNFa. Background fluorescence
was deduced from unstimulated, media-only, and negative control
wells, Fig. 2C. Pestle and SPICE software [28], version 5.1; http://
exon.niaid.nih.gov/spice, was used to subtract background fluores-
cence and graphically summarize the T cells into IFN-c secreting
and non secreting subsets.
Tests were considered positive if at least 0.01% of gated T-cells
were responsive after subtracting the background fluorescence.
Poly-functionality was defined as the simultaneous secretion of
at least three T-cell functions. Global T-cell responses were initially
compared across gated IFN-c positive and negative populations. To
assess responses from only antigen-specific stimulation, and to
clarify graphical illustrations of the data, subsets that lacked all
evaluated T-cell functions (IFNcIL2PerfTNFa) were some-
times not displayed on some graphs.
2.6. Statistical analysis
Frequency analyses and graphical illustrations of the expressed
functions were performed using SPICE software version 5.1 and
Prism 5 (Graph Pad Software, Inc., San Diego, CA, USA). SPICE auto-
matically log-transformed the datasets, and used an in-built stu-
dent’s T-test to compute statistical differences between
expressed CD4 and CD8 functions across IFN-c positive and IFN-
c negative T-cells. Proportions of responding subsets were com-
pared across IFN-c positive and IFN-c negative T-cells using Fish-
er’s Exact test (Epi Info 7.2; https://www.cdc.gov/epiinfo/pc.
html). Comparisons were considered significantly different if p-
values were 0.05. When differences across the seven subgroups
of co-expressed functions were compared, Bonferroni’s adjustment
for multiple testing was applied, and only p-values 0.0071 were
considered significant.
3. Results
3.1. IFN-c negative CD4+ T-cells from HIV infected individuals can
secrete IL-2, TNF-a, and Perforin
We first compared IFN-c positive and negative CD4+ (CD3
+CD8CD4+) T-cells demarcated by hierarchical flow cytometry
Fig. 2. Gating strategy for defining antigen-specific T-cell functions using flow cytometry. This figure summarizes procedures for demarcating antigen-specific T-cells using
FlowJo software, FlowJo, LLC. (i) First, lymphocytes were identified; (ii) plotted on forward scatter height (FSC-H) against forward scatter area (FSC-A) to select single cells, (iii)
subjected to CD14, CD19, and Aqua antibody exclusion to remove B-cells, monocytes, and dead cells, respectively, (iv) before gating out CD3+ lymphocytes, A. Double positive
T cells (CD3+CD4+CD8+) were excluded, while CD4+ (CD3+CD8CD4+) and CD8+ (CD3+CD4CD8+) T cells were selected for subsequent evaluations, B. Secretion of IFN-c, IL-
2, TNF-a, and Perforin was then quantified using cytokine-specific plots derived from FlowJo software, C. Finally, the co-expressed T cell functions were further distinguished
into singly expressed, concurrently expressed, and non-functional subsets using FlowJo generated Boolean gating.
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gating for the expression of HIV-specific IFN-c, IL2, Perforin, and
TNF-a. Overall, expression of other functions (IL2, Perforin or
TNF-a) was significantly higher in IFN-c negative CD4 T cells
(0.58%) than in the IFN-c positives (0.02%), p < 0.0001, in-built
SPICE student’s T-test, Fig. 3A. Considering only the seven co-
expressing T-cell functional profiles, responses were of signifi-
cantly higher frequencies in five of seven IFN-c negative CD4+ T-
cells compared to none of the seven IFN-c negative functional sub-
sets; p = 0.02, Fisher’s Exact test the 3B. Considering the activated
chronic status of the assessed population, and the indiscrete popu-
lation of singly secreted Perforin, we adopted a more stringent
approach to estimating newly secreted Perforin. Accordingly, sin-
gly expressed Perforin was ignored; and only Perforin co-
expressed with another T-cell function was considered newly
secreted. Correspondingly, Perforin co-expression with TNF-a (Per-
forin + TNF-a+) and IL-2 (Perforin + TNF-a+IL2+) was significantly
higher in IFN-c negative CD4+ T-cells subsets, p = 0.005 and
0.001, respectively, SPICE in-built T-test, Bonferroni adjusted sig-
nificance of p = 0.0071 Fig. 3B.
Of the responding IFN-c positive CD4+ cells, 24.7% were poly-
functional; 28.3% secreted only IFN-c, while the rest co-
expressed IFN-c responses with mainly IL2 or TNF-a, Fig. 3C.
Among the IFN-c negative CD4+ T-cells, 96% lacked all evaluated
responses (IFNcIL2PerfTNFa subset), Fig. 3D; this non-
responsive subset was ignored in subsequent comparisons to
ease statistical analysis and to clarify the graphical illustrations.
Considering only the responsive IFN-c negative CD4+ T-cells,
only 0.5% were polyfunctional, 2.2% co-expressed two functions,
and 97% predominantly secreted single functions of Perforin,
Fig. 3E.
Fig. 3. IFN-c negative T-cells from HIV infected individuals’ can produce detectable IL-2, TNF-a and/or Perforin. This figure compares IFN-c positive and negative T-cells for
frequencies of co-expressed T-cell functions after stimulation with HIV-1 consensus M (Con M) Gag antigens. FlowJoTM generated booleans were uploaded onto PestleTM
software to subtract backgrounds; and SPICETM software, version 5.1 (NIAID) to stratify the CD4+ T-cells into IFN-c positive and negative cells (IFN-c overlaying). The T-cell
responses were graphically summarized into eight functional combinations of IFN-c secreting (red) and non-secreting (blue) cells using SPICETM, A, and B. Plus (+) and minus
() signs below the x-axis indicate presence or absence of the specified function(s), respectively. Bars represent the frequencies (%) of expressed function(s) by the parent
cells; and error bars represent their standard deviations. P values of 0.05 were considered statistically significant, and were denoted with * sign above the bars to indicate p-
values  0.05, ** to indicate p-values  0.01, and *** to indicate p-values of 0.001. Bonferroni adjustment for multiple testing was applied when responses were compared
across the functional combinations, in that case, P values of 0.0071 were considered significant. Cells that did not secrete any of the evaluated responses have been excluded
to ease clarity. The y-axis has been cut for better visual presentation of the data, B. The pie charts summarize frequencies of indicated CD4+ T-cell functions in IFN-c positive
cells (C); in IFN-c negative including non-secreting cells (D), and the IFN-c negative without non-secreting cells (E). Pie arcs represent individual contributions of specified
functions to the total T-cell response.
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3.2. High proportions of IFN-c negative CD8+ T-cells expressed
Perforin, TNF-a and IL2 functions in response to HIV peptides
We next compared flow cytometry gated CD8+ (CD3
+ CD4CD8+) T-cells from HIV-infected individuals for virus-
specific IL-2, Perforin and TNF-a expression across subsets of
IFN-c positive and IFN-c negative T-cells. Similar to the CD4+ T-
cells, IFN-c negative CD8+ T-cells expressed other functions of IL-
2, Perforin and TNF-a at higher frequencies (3.24%) than the IFN-
c positive T-cells (0.14%); p < 0.0001, SPICETM in-built T-test,
Fig. 4A. Of the seven IFN-c negative co-expressing CD8+ T-cell
functional subsets, three had significantly higher CD8+ T-cell
responses, p  0.0071, Bonferroni corrected, SPICE in-built T-test.
Like with CD4+ cells, co-expression of Perforin and IL-2 or TNF-a,
more representative of newly secreted HIV-specific Perforin, was
significantly higher in three IFN-c negative CD8+ T-cell subsets,
Fig. 4B. Of the responding IFN-c positive CD8+ cells, 42% secreted
monofunctional IFN-c: the rest co-expressed IFN-c with mostly
TNF-a, while 9.4% were polyfunctional, Fig. 4C. Of the IFN-c nega-
tive CD8+ T-cells, 76% lacked all evaluated T-cell responses, Fig. 4D.
When all non-responsive cells were removed, 99.5% of the func-
tional IFN-c negative CD8+ T-cells secreted singly secreted Per-
forin, Fig. 4E. Taken together, these data underscored the
importance of comprehensively evaluating both IFN-c positive
and IFN-c negative T-cells when assessing immune correlates of
protection from infection.
3.3. T-cells from HIV-1 infected individuals had a high intrinsic ability
to secrete T-cell functions in response to polyclonal stimulation with
SEB
We then evaluated if specimens from HIV infected individuals
has lost their intrinsic capability to secrete T-cell responses. PBMCs
from HIV-1 infected individuals were stimulated with SEB super
antigen to determine the maximum secretion of functions in IFN-
c positive and negative T-cells. SEB-stimulated cells secreted all
Fig. 4. Some IFN-c negative CD8+ T-cells express high proportions of Perforin, TNF-a and/or IL2 functions. This figure compares frequencies of co-expressed CD8+ T-cell
functions in IFN-c positive and negative cells in response to HIV-1 Con M stimulation, A. FlowJo derived CD8+ T-cell booleans were stratified as 8 distinct combinations of IFN-
c secreting (red) and non-secreting (blue) functional profiles using SPICETM software, version 5.1 (NIAID). Positive signs (+) below the x-axis indicate presence of specified
function(s), and negative signs indicate absence of that function. The bars represent frequencies (%) of parent T-cells expressing a specified combination of functions; error
bars represent standard deviations. P values of 0.05 were considered statistically significant, and were denoted with a* sign above the bars to indicate p-values 0.05, ** to
indicate p values 0.01, and *** to indicate p values 0.001. Bonferroni adjustment was applied to compare responses across subgroups, in such cases P values of 0.0071
were considered significant. Cells that did not secrete any functions have been excluded to improve clarity. The y-axis has been cut to improve visual presentation of the data,
B. Cell populations were also summarized as pie charts with IFN-c response overlaid, to illustrate frequencies of CD8+ T-cells that are secreting IFN-c (C); CD8+ T –cells that
are IFN-c negative including non-secreting cells, (D), and IFN-c negative CD8+ T-cells without the non-secreting cells E. Pie arcs represent the individual contribution of each
function to the total T-cell response.
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the evaluated functions. We found that both CD4+ and CD8+ T-cell
responses were significantly increase when the specimens were
stimulated with SEB, p < 0.0001 and p = 0.022, respectively, sup-
plementary Fig. 3 TNF-a predominated in both IFN-c positive
and negative subsets. Like for HIV stimulation, SEB-stimulated,
IFN-c negative CD4+ T-cells secreted significantly higher responses
(2.14%) than the IFN-c positive cells (0.4%), p < 0.0001, SPICE in-
built student’s T-test, Fig. 5A. Frequencies of responses were signif-
icantly higher in four IFN-c negative CD4+ T-cell subsets
(p  0.00071, Bonferroni adjusted), while three subsets lacked sig-
nificant difference across the IFN-c positive and negative pheno-
types, Fig. 5B. Of the detectable responses from the IFN-c
positive CD4+ T-cells, 53% were polyfunctional (upper Fig. 5C).
On the other hand, 69.4% of the IFN-c negative responses were
monofunctional, lower Fig. 5C.
Similar to CD4 cells, the overall SEB-stimulated responses were
significantly higher in IFN-c negative (3.0%) than in the positive
(1.9%) CD8+ T-cells, p = 0.031, SPICE in-built student’s T-test,
Fig. 5D. Contrary to the CD4+ cells, frequencies of SEB-stimulated
CD8+ T-cell functions were significantly higher in four of seven
IFN-c positive functional subsets compared to one in the corre-
sponding IFN-c negative subsets, (p  0.0071, Bonferroni
adjusted), Fig. 5E. Like in CD4+, the IFN-c positive CD8+ T-cells
were more polyfunctional (upper Fig. 5F), while 95% of the corre-
sponding IFN-c negative subsets expressed singly secreted Per-
forin, lower Fig. 5F. Taken together, these data exhibited a
reduction in non-IFN-c responses from the cryopreserved T-cells
largely affecting the CD4+ T-cell subsets.
3.4. Virus-specific T-cell responses were detectable in ELISpot assay
screen-out PBMCs from healthy volunteers
Finally, we assessed the extents of missed Adenovirus-specific
IL-2, TNF-a and Perforin in PBMC specimens from healthy volun-
teers that had been screened as IFN-c negative using ELISpot assay,
and were pre-qualified for participating in vaccine trials. The ELI-
Spot assay cut off for a positive response was 100 SFU/106 PBMCs
after subtracting thrice the background. Thus, low levels of IFN-c
detection would be expected when such screen out specimens
are subjected to flow cytometry. Generally, this population was
less activated; T-cell responses were generally low compared to
the HIV cohort. Overall, we found virus specific IL-2, TNF-a and
Fig. 5. T-cells from HIV-Infected individuals were capable of secreting high frequencies of SEB-stimulated T-cell responses. This figure summarizes the overall SEB-stimulated
IFN-c positive (blue) and negative (red) CD4+ T-cell responses, (A) The cells stratified into eight functional combinations of IFN-c positive and negative cells, with bars
representing frequencies (%) of expressed IL-2, TNF-a, and Perforin functions, and error bars the standard deviations. P values  0.05 are considered statistically significant,
and are denoted with a * sign above the bars to indicate p-values  0.05; ** indicates p values  0.01 and *** indicates p values  0.001, (B) Pie charts summarize the
proportions of functions in IFN-c positive (upper C) and negative CD4+ T-cells (lower C). Pie arcs represent contributions of each function to the total response. Similarly,
frequencies of IFN-c positive and negative CD8+ T-cells are shown (D), distributed into eight profiles of functions (E), and summarized as pie charts and pie arcs, F.
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Perforin responses in both CD4+ and CD8+ T-cells. Like with HIV,
these responses were higher in the IFN-c negative CD4+ (Fig. 6A)
and CD8+ (Fig. 6B) T-cell subsets.
4. Discussion
In this study, we evaluated the extent of missed T-cell
responses when antigen-induced IFN-c detection was used as the
basis for determining subsequent estimation of co-expressed
TNF-a, IL-2, Perforin T-cell responses in cryopreserved cells. Using
cells from chronic HIV-1 infected individuals; we showed that
although IFN-c positive T-cells were more polyfunctional, HIV-
specific IL-2, Perforin, and TNF-a responses also occurred at signif-
icantly higher proportions in the responsive IFN-c negative T-cells.
This was observed for both CD4+ and CD8+ T-cell phenotypes. The
higher T-cell polyfunctionality among IFN-c positive cells under-
scored their importance in assessing T-cell functional responses.
However, the substantial levels of missed responses when IFN-c
negative cells are omitted highlights the importance of compre-
hensively evaluating all T-cell functions regardless of the IFN-c
ELISpot responsive status of the test PBMCs. Expression of TNF-a,
IL-2, Perforin and/ or MIP-1b responses in IFN-c negative T-cells
has been reported before [29]. Here, we specifically compared
the proportions of other T-cell functions concurrently expressed
in IFN-c secreting and non-secreting T-cells. A study conducted
in HIV-1 chronically infected disease progressors, viremic con-
trollers and elite controllers found that Perforin and MIP1a
responses occurred at significantly higher proportions in IFN-c
negative CD8+ T-cells from elite controllers than in chronic pro-
gressors, supporting their importance [15]. The authors concluded
that CD8+ T-cell expression of Perforin was a correlate of HIV con-
trol. In the same study, significantly more CD8+ T-cells from
chronic progressors secreted IFN-c compared to elite controllers;
this implied that IFN-c expression is not necessarily associated
with controlling disease progression.
Within the scope of this study, we were not able to explain why
measurable T-cell functions were much lower in IFN-c secreting T-
cells than in the corresponding IFN-c non-secreting phenotype. We
do not believe that these differences were due to sampling of an
aging T-cell population. However, we used cryopreserved PBMCs
in all our evaluations; and this could partly explain why responses
in IFN-c positive cells were quite low. A recent study on stored
PBMCs showed that cryopreservation can result in up to five-fold
reduction in antigen-specific IFN-c producing CD4+ effector T-cell
functionality while the IFN-c negative phenotype remains rela-
tively unaffected [30]. Also, greater expression of IFN-c has been
linked to the late stages of effector T-cell lifespan [12], and T-cell
exhaustion [31–33]; the low levels of IFN-c production may also
suggest that our samples were not in a late stage. Unfortunately,
due to specimen volume limitations, we were not able to specifi-
cally test for the presence of T-cell exhaustion. Although we lacked
clinical information about the duration of HIV infection among the
ART-naïve individuals from whom we isolated PBMCs, their med-
ian CD4 counts of >500 cells/ll, and viral load of about 15,000
copies/ml, did not imply T-cells exhaustion. Also, the high propor-
tion of T-cells responding to SEB antigen indicated that our T-cells
were immunologically competent and therefore able to optimally
secret cytokines and functions when maximally stimulated with
antigens.
Often, IFN-c ELISpot assay is used to first identify individuals
that produce IFN-c in response to specified tested antigens; these
are then assessed for production of other immune functions. We
used flow cytometry to evaluate the extent of missed detection
of specified T-cell responses by such screening approaches.
Adenovirus-specific TNF-a, IL-2, and Perforin expression in IFN-c
negative CD4+ and CD8+ T-cells from healthy IFN-c ELISpot nega-
tive individuals were quantified. We found that even cells from
IFN-c ELISpot negative individuals produce substantial T-cell func-
tions that are detectable by intracellular cytokine staining flow
cytometry. We showed that subsequent evaluations of other func-
tions using only IFN-c ELISpot assay positive specimens would sig-
nificantly under estimate the detection of Perforin, a function
established to be critical for viral control [15]. Two studies that
compared use of ELISpot and flow cytometry assays for detection
of responding T-cells showed that virus-specific T-cells were
underestimated when immune responses were measured with
IFN-c ELISpot assay alone [31,34]. Also, T-cells from HIV seroposi-
tive persons have been reported to respond differently to different
HIV-1 epitopes, some of which can drive expression of immune
functions other than IFN-c [29,35]. If the ELISpot assay is used to
determine or screen for responses to these epitopes, then T-cells
might be incorrectly identified as being non-responsive to antigen.
In HIV-infected individuals and healthy controls, higher propor-
tions of IFN-c negative CD4+ and CD8+ cells secreted mostly
monofunctional Perforin. This predominance of singly expressed
Perforin should be interpreted with caution. The ART-naïve cohort
we evaluated was in a state of chronic activation due to continued
Fig. 6. T-cell responses were detectable in some ELISpot assay screen-out IFN-c
negative cells from healthy volunteers. This figure illustrates T-cell responses
detected in PBMCs from healthy individuals that were initially screened as IFN-c
ELISpot assay negative to Adenovirus peptides. These PBMCs were then stimulated
with Adenovirus antigens for the co-expression of IL-2, TNF-a, and Perforin T-cell
functions using flow cytometry. Bars indicate proportions of expressed IL-2,
Perforin, and TNF-a in CD4+ T-cells, error bars indicate standard deviations (A).
Positive signs below the x-axis indicate presence of specified function(s); and
negative signs indicate absence of the specified function(s). Responses in IFN-c
positive and IFN-c negative CD8+ T-cells are similarly shown in B.
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presence of viral antigen. The evaluated HIV-specific T-cells were
not in a true resting state, and possibly had accumulated levels
of pre-existing Perforin in vivo. Perforin gates were particularly dif-
ficult to distinguish, suggesting Perforin was likely pre-existing.
We used the anti-Perforin clone 48 antibody, which was previously
shown to stain resting CD8+ T-cells equivalently to the dG9 Per-
forin clone [36]. Those authors discouraged use of dG9 Perforin
because it could not recognize new Perforin that is trapped in
the ER/Golgi compartment. They also found the B-D48 Perforin to
be more associated with elite control of HIV-1. Clone B-D48 recog-
nizes both pre-formed Perforin in cytotoxic granules and new Per-
forin secreted in response to antigenic stimulation, while clone dG9
recognizes Perforin within cytotoxic granules. Although the B-D48
Perforin clone does not specifically distinguish pre-formed from
newly secreted Perforin, Hersperger et al, [15] showed that newly
secreted Perforin co-expresses with other cytotoxic functions, and
largely bypasses the cytotoxic granules. Therefore, focusing on only
cells that have degranulated would most certainly underestimate
the levels of secreted Perforin. Thus, we adopted a more stringent
approach of assessing D48 Perforin co-expressing with another T-
cell function as the one representing newly secreted, antigen-
stimulated Perforin in activated T-cells. We still found that co-
expressed Perforin occurred at significantly higher frequencies in
both CD4+ and CD8+ IFN-c negative T-cell subsets underscoring
the potential for loss of critical cytolytic functions when IFN-c neg-
ative cells are ignored in T-cell functional analyses.
We found qualitative differences in T-cell functions expressed
by IFN-c positive and negative T-cells. Poly-functionality was pre-
dominantly found in IFN-c positive T-cells, and IFN-c negative T-
cells were largely mono-functional. Poly-functionality of virus-
specific T-cell responses is associated with better HIV-1 disease
control [37,38], and CD8+ T-cells from HIV-1 disease elite-
controllers are more likely to express single functions of either Per-
forin or MIP-1b, than CD8+ T-cells from HIV rapid disease progres-
sors [15,16]. Likewise, in vivo monofunctional Perforin secretion in
CD4+ T-cells has been linked with control of viral infections in
C57BL/6 mice [39]. Significantly higher proportions of IFN-c nega-
tive CD4+ and CD8+ T-cells expressed single functions of TNF-a
and IL-2 respectively compared to the IFN-c secreting phenotype.
Single function expression of IL-2 than IFN-c was similarly found
among T-cells isolated from adults who received a Hepatitis B
booster vaccine [38] A study that examined whether CD8+ T-cells
are helpful in preventing HIV viral replication showed that CD8+ T-
cells that exhibited the strongest viral inhibition were sometimes
monofunctional, and expressed functions other than IFN-c [40].
Finally, IFN-c secretion does not always correlate with cytotox-
icity in virally infected T-cells in vitro [41]. These findings as well
as our own indicate that evaluation of immunogenicity based on
selection of IFN-c secreting cells, in flow cytometry gating analysis
and/ or ELISpot selection, may underestimate the potentially useful
cytotoxic responses in both CD4+ and CD8+ T-cells. In our study,
Perforin, a cytotoxic protein found in the granules of cytotoxic T-
cells, was the primary function that was expressed alone and with
other functions among IFN-c negative T-cells. It has previously
been shown that IL-2, which promotes proliferation of CD8+ and
CD4+ T-cells and up-regulates the expression of Perforin are rarely
co-expressed in the same cell [42,43]. In one of these papers [42],
the authors found co-expression of IL-2 and Perforin in IFN-c+ CD8
+ T-cells to be rare but to be associated with protection. In our
study, CD8+ IFN-c positive T-cells did not co-express IL-2 and Per-
forin in response to HIV-1 peptide stimulation. In contrast, we
observed a significant proportion of IFN-c negative T-cells co-
expressing both these functions after HIV-1 Con M peptide stimu-
lation further underscoring the importance of comprehensive eval-
uation of T-cells regardless of IFN-c ELISpot status, especially when
evaluating co-expression of Perforin.
This study had some limitations; apart from IFN-c, we charac-
terized polyfunctionality based on secretion of at least three func-
tions. If we had measured the expression of more functions, some
T-cells currently classified as mono-functional, may have been bi-
or poly-functional. Also, we were unable to evaluate the presence
of MIP1a or CD107a functions that commonly co-express with
Perforin to effect cytolytic functions important for HIV-disease
control. In addition, the overall sample size of persons from whom
we isolated PBMCs was fairly small, and we did not have informa-
tion on how long they had been HIV infected. Finally, we were
unable to evaluate T-cell exhaustion, which would have helped
estimate the stage of differentiation of our T-cells.
All the same, our findings show that some IFN-c negative cells
can produce cytokines. Therefore conventional approaches of ana-
lyzing flow cytometry data by setting cytokine gates based on IFN-
c,or use of IFN-c ELISpot as a surrogate marker for further evalua-
tion of virally induced immune responses may underestimate the
extent of antigenic-specific T-cell immune response. Data from
the healthy volunteers has implications for evaluating T-cell
responses in vaccine trials. Evaluations of immunogenicity in
response to viral antigens should not only evaluate T-cell respon-
siveness among IFN-c producing cells but also among those T-
cells that do not express IFN-c. HIV vaccine development studies
may benefit from expanding the evaluation of T-cell populations
used to predict immunogenicity.
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